Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Tumor-site directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors. [Human RNAseq inducible]

ABSTRACT: Tumor-site directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors. [Human RNAseq inducible]

PROVIDER: PRJNA1199936 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR31773608.fastq.gz	Fastqsanger.gz
	SRR31773609.fastq.gz	Fastqsanger.gz
	SRR31773610.fastq.gz	Fastqsanger.gz
	SRR31773611.fastq.gz	Fastqsanger.gz
	SRR31773612.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

Tumor-site directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors. [Human RNAseq inducible]

Project description:The efficacy of Chimeric Antigen Receptor (CAR) T cells against solid tumors is limited by immunosuppressive factors in the tumor microenvironment (TME) including adenosine, which suppresses CAR T cells through activation of the A2A receptor (A2AR). To overcome this, CAR T cells were engineered to express A1 receptor (A1R), a receptor that signals inversely to A2AR. Using murine and human CAR T cells, constitutive A1R overexpression was demonstrated to significantly enhance CAR T cell effector function albeit at the expense of CAR T cell persistence. Through a novel CRISPR/Cas9 “knock-in” approach we demonstrated that CAR T cells engineered to express A1R in a tumor-localized manner, led to enhanced anti-tumor efficacy dependent on the transcription factor IRF8 and was transcriptionally unique when compared to A2AR deletion. This data provides a novel approach for enhancing CAR T cell efficacy in solid tumors and provides proof of principle for site-directed expression of factors that promote effector T cell differentiation.

2025-03-16 | GSE284618 | GEO

Tumor-site directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors. [CD8 inducible human RNAseq]

2025-03-16 | GSE284619 | GEO

Tumor-site directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors. [human ATACseq]

2025-03-16 | GSE284616 | GEO

Tumor-site directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors. [human RNAseq constitutive]

2025-03-16 | GSE284615 | GEO

Tumor-site directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors. [Mouse RNAseq constitutive]

2025-03-16 | GSE284614 | GEO

Tumor-site directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors. [CD8 inducible human RNAseq]

Project description:Tumor-site directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors. [CD8 inducible human RNAseq]

| PRJNA1199945 | ENA

Tumor-site directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors. [human ATACseq]

Project description:Tumor-site directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors. [human ATACseq]

| PRJNA1199942 | ENA

Tumor-site directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors. [Mouse RNAseq constitutive]

Project description:Tumor-site directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors. [Mouse RNAseq constitutive]

| PRJNA1199924 | ENA

Tumor-site directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors. [human RNAseq constitutive]

Project description:Tumor-site directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors. [human RNAseq constitutive]

| PRJNA1199937 | ENA

NR4a knock-down in HER2 CAR-T cells improves T cell longevity and promotes solid tumor eradication [RNA-Seq]

Project description:Chimeric antigen receptor (CAR)-T cell therapy targeting human CD19 have demonstrated clinical efficacy against B-cell malignancies. However, CAR-T cell therapy's efficacy against solid tumors is limited due to factors like low tumor-associated antigens, infiltration rate, and T cell exhaustion. We have shown that deleting NR4a genes in CAR-T cells prevents T cell exhaustion and improved their therapeutic effects on solid tumors in a mouse model. To further explore this for human, we deleted all three NR4a family factors in CAR-T cells that recognize Epidermal Growth Factor Receptor type 2 (HER2) using the CRISPR/Cas9 system. These modified CAR-T cells (NR4a-TKO CAR-T) exhibited resistance to exhaustion, increased tumor-killing activity, and higher efficacy in tumor regression and survival rate in a human lung carcinoma model in mice. The enhanced therapeutic effects were associated with increased cytokine expression, reduced exhaustion-related gene expression, and improved persistence within tumors. We propose that targeting NR4a could be a promising strategy for developing superior CAR-T cells against solid tumors.

2024-08-28 | GSE241456 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data